Pediatrics Medical News about growth failure; children; primary IGF-1; mecasermin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Therapeutics and Clinical Risk Management, 07/17/09

Fintini D et al. – Growth hormone insensitivity syndrome (GHI) or insulin–like growth factor–1 (IGF–1) deficiency (IGFD) is characterized by deficit of IGF–1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF–1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF–1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug Admin istration only in 2005 and in Europe by the European Medicines Agency in 2007. To date, few studies are available on long–term treatment with mecasermin in IGFD patients and some of them have a very small number of subjects. In this review the authors discuss briefly clinical features of severe primary IGFD, laboratory findings, and indications for treatment. Results of long–term therapy with rhIGF1 (mecasermin) in patients affected by severe primary IGFD and possible side effects are explained.

<< Previous
Whole Gastrointestinal Transit Time is Associated with Clinical...

Next >>
Impaired somatic growth and delayed lung development in infants...